Author(s):
Pawan N. Karwa, Jyoti K. Soundarmal, Pallavi S. Shinde, Swapna R. Jalde
Email(s):
Karwapawan99@gmail.com
DOI:
10.52711/2231-5713.2022.00008 
Address:
Pawan N. Karwa, Jyoti K. Soundarmal, Pallavi S. Shinde, Swapna R. Jalde
Gurukrupa Institute of Pharmacy [Degree] Malipargaon, Phata, Majalgaon, Dist: Beed, 431129.
*Corresponding Author
Published In:
Volume - 12,
Issue - 1,
Year - 2022
ABSTRACT:
Mucormycosis is an emerging infection associated with high mortality. These fungi are very common molds to which exposure is probably quite frequent, still, clinical disease is rare and affects severely immunocompromised patients or patients with diabetes mellitus. Mucormycosis is manifested by a wide variety of syndromes, devastating rhino-orbitalcerebral and pulmonary infections are the major presentation. The diagnosis of mucormycosis relies upon the identification of organisms in tissue, however culture often yields no growth. Mucormycosis are serious infections caused by filamentous fungi of the order Mucorales. Mucormycosis is a life-threatening infection caused by fungi of the order Mucorales. Recent reclassification has abolished the order Zygomycetes and placed the order Mucorales in the subphylum Mucormycotina. We report five cases of mucormycosis of patients hospitalized, In 2021. They were 4 males and 1 female, mean age 60 years. All patients were treated with amphotericin B and posiconazole.
Cite this article:
Pawan N. Karwa, Jyoti K. Soundarmal, Pallavi S. Shinde, Swapna R. Jalde. Mucormycosis: A Lethal Disease. Asian Journal of Pharmacy and Technology. 2022; 12(1):41-6. doi: 10.52711/2231-5713.2022.00008
Cite(Electronic):
Pawan N. Karwa, Jyoti K. Soundarmal, Pallavi S. Shinde, Swapna R. Jalde. Mucormycosis: A Lethal Disease. Asian Journal of Pharmacy and Technology. 2022; 12(1):41-6. doi: 10.52711/2231-5713.2022.00008 Available on: https://ajptonline.com/AbstractView.aspx?PID=2022-12-1-8
REFERENCE:
1. Hariprasath Prakash and Arunaloke Chakrabarti, Global Epidemiology of Mucormycosis. Jurnal of Fungi 2019; 5(26): doi:10.3390/jof5010026www.mdpi.com/journal/jof
2. A. Mallis, S.N. Mastronikolis, S.S. Naxakis, A.T. Papadas, Rhinocerebral mucormycosis: an update, European Review for Medical and Pharmacological Sciences. 2010; 14: 987-992
3. Monte Junior ESD, Santos M, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: A case report. Clin Endosc. 2020; 53(6): 746–9.
4. Bitar D, Van Cauteren D, Lanternier F et al. Increasing incidence of zygomycosis (Mucor-mycosis), France, 1997–2006. Emerg Infect Dis., 2009; 15: 1395–1401.
5. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clinical Infectiou sDiseases. 2012; 54(suppl_1): S23-34.
6. E. Bouza, P. Mun˜oz and J. Guinea, Mucormycosis: an emerging disease?, Clinical Microbiology and Infection, 2006; 12(7)
7. Luna B, Drew RH, Perfect JR. Agents for treatment of invasive fungal infections. OtolaryngolClin North Am [Internet]. 2000; 33(2): 277–99. Available from: http://dx.doi.org/ 10.1016/ S0030 -6665(00)80005-5
8. Yamazaki T, Kume H, Murase S, Yamashita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J ClinMicrobiol 1999; 37: 1732–1738.
9. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952.
10. Sundaram Challa, Mucormycosis: Pathogenesis and Pathology, Current Fungal Infection Reports 2019; 13: 11–20 https://doi.org/ 10.1007/s12281-019-0337-1
11. Ashraf S. Ibrahim, Brad Spellberg, Thomas J. Walsh, and Dimitrios P. Kontoyiannis, Pathogenesis of Mucormycosis, Clinical Infectious Diseases ·February 2012, https:// www.researchgate.net/publication/221749686
12. Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopusoryzae to extracellular matrix components. Eur J Cell Biol 1996; 70: 76–83.
13. Spellberg B, Edwards J, Ibrahim A. Novel perspectives on Mucormycosis: pathopsyology, presentation, and management. ClinMicrobiol Rev. 2005; 18(3): 556-69.
14. https://www.webmd.com/lung/mucormycosis-black-fungus-infection
15. Nikolaos V. Sipsas, Maria N. Gamaletsou, Amalia Anastasopoulou and Dimitrios P. Kontoyiannis. Therapy of Mucormycosis, Jurnal of Fungi 2018; 4: 90, doi:10.3390/ jof4030090 www.mdpi.com/journal/jof